Drug Search Results
More Filters [+]

Ketamine

Alternative Names: ketamine, ketalar, ketamina, SLS-003, SLS003, ketamin
Latest Update: 2024-06-20
Latest Update Note: News Article

Product Description

Ketamine is used by medical practitioners and veterinarians as an anaesthetic. It's sometimes used illegally by people to get high.

Mechanisms of Action: NMDA Antagonist,Excitatory Amino Acid Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ketamine

Countries in Clinic: Australia, Canada, China, Egypt, United States

Active Clinical Trial Count: 24

Highest Development Phases

Phase 3: Bipolar Disorder|Colorectal Cancer|Depressive Disorder, Major|Digestive System Cancer|Gastrointestinal Cancer|Headache Disorders|Intestinal Diseases|Liver Cancer|Mouth Cancer|Mucositis|Oropharyngeal Cancer|Skin Cancer|Suicidality

Phase 2: Cataract|Depressive Disorder|Depressive Disorder, Treatment-Resistant|Healthy Volunteers|Rett Syndrome|Stress Disorders, Post-Traumatic

Phase 1: Anorexia|Morphine Dependence|Pain, Postoperative

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SevereBD

P3

Active, not recruiting

Suicidality|Bipolar Disorder

2024-12-31

95%

Ketamine Trial for Acute suicidality (KETA)

P2

Active, not recruiting

Suicidality

2024-06-08

KetHead

P3

Recruiting

Headache Disorders

2023-10-01

2021-004927-34

P2

Active, not recruiting

Depressive Disorder, Treatment-Resistant

2023-07-28

Recent News Events